In the largest effort to date to standardize performance metrics of the cancer diagnostic across products, researchers say the products can likely detect advanced tumors reliably, but early-stage malignancies would remain a challenge.

Some experts blame our modern, sugary diet, while others think that gut microbiome changes and sedentary lifestyles may play a role. Altogether, the causes are far from clear.

US Preventive Services Task Force recommends genetic testing for mutations in the cancer-related genes for more—but not all—women.

An artificial intelligence program called a neural network exceeds radiologists’ ability to detect malignancies, but more testing is needed before using the program clinically.

H. Gilbert Welch, a health policy expert who has advocated against superfluous cancer screening, published another Dartmouth researcher’s work, according to the university administration.

3-D balls of cells can be used to screen for potential cancer drugs.

Mutations in the TP53 gene appear to influence the prognosis and likelihood of future cancers in pediatric leukemia patients.

The new diagnostic works by identifying cancer-associated proteins and DNA in patient blood.